This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing Senior Editor Ben Adams. We're diving into our recent spin on March Madness at Fierce. This time around, Fierce Biotech kicked off its inaugural Best Biotech Name tournament, while over at Fierce Pharma Marketing, we held our biannual Drug Names tournament. The editors discuss what makes a company or drug name tick, what to steer clear of, and how the entire competition played out.  To learn more about the topics in this episode:  #FierceMadness: AstraZeneca and Ionis cruise to victory as Wainua trounces Lilly's Mounjaro for the tournament win#FierceMadness: The Best Biotech Name Tournament—A champion is CROWNEDSee omnystudio.com/listener for privacy information.

Jeff Beck of BioCare is in the hotseat for this edition of The Top Line. Beck is the Chief Development Officer at the company, which stands tall as a pioneer in specialty product distribution with over 40 years of experience dating back to hemophilia therapies. During the conversation, Beck provides an inside look at the rapidly evolving specialty distribution landscape. He outlines how the patient-centric model is working well and is supported by efficient supply chains. However, the future will demand increasing personalization to handle a wider range of complex product archetypes like cell and gene therapies. This, Beck says, calls for expanded data capabilities around inventory visibility, site analytics and dissecting the patient journey. Beck also goes on to explain how new regulations like the Inflation Reduction Act will impact specialty distribution, and why emerging manufacturers will increasingly rely on experienced partners like BioCare. Don't miss this insightful discussion on meeting today's specialty distribution needs while paving the way for tomorrow's innovations. Tune in now.See omnystudio.com/listener for privacy information.

This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024.  Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. With a notable number of layoff rounds marking the start of the year, they examine the factors behind this ongoing challenge while also highlighting positive industry developments. To learn more about the topics in this episode:  No reprieve for biopharma layoffs in Q1: Fierce Biotech analysisFierce Biotech Layoff Tracker 2024See omnystudio.com/listener for privacy information.

This week on “The Top Line,” we explore peripheral arterial disease, a serious health issue that is often overlooked and undermanaged.   Join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of the Peripheral Vascular Intervention & CLI Program at Rush University Medical Center. They discuss the hidden dangers of PAD, and Dr. Madassery emphasizes the importance of early detection. He also discusses the launch of the PAD Pulse Alliance, a collaborative effort among vascular health experts aimed at raising awareness, improving early detection and reducing amputation rates.  To learn more about the topics in this episode:  Philips-supported campaign wants Americans to 'get a pulse on PAD' amid ignorance of the diseaseJohnson & Johnson 'Save Legs. Change Lives.' campaign brings PAD amputation awareness to Black communityBayer and J&J's Xarelto reduces ischemia risk for PAD patients after revascularization surgery  See omnystudio.com/listener for privacy information.

This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry. Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode. They also discuss the details of the special report and share some of the stories behind the numbers.  To learn more about the topics in this episode:   Biotech's top money raisers of 2023Fierce Biotech Fundraising Tracker 2024Fierce Biotech Fundraising Tracker 2023  See omnystudio.com/listener for privacy information.

This week on “The Top Line,” we explore the European biotech investment landscape.  Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector.  To learn more about the topics in this episode:  'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023'Optimism' at Jefferies conference, but don't expect biotech IPO boost soon, says Sofinnova chair  See omnystudio.com/listener for privacy information.

This week on “The Top Line,” we’re diving into the topic of diversity in clinical trials, examining both the progress made and the ongoing work needed to ensure inclusivity.  In this episode, Fierce Biotech Senior Editor Annalee Armstrong engages in a conversation with Karen Correa, Ph.D., Head of Global Clinical Operations at Takeda and Executive Sponsor of Trial Diversity. Correa shares her insights into why it's imperative for pharmaceutical companies to adapt and prioritize diversity in their clinical trials, while also discussing the initiatives Takeda has undertaken in this area.  To learn more about the topics in this episode:  Clinical trial diversity craters out to lowest level in 10 years, IQVIA findsASCO, ACCC become latest to call for clinical trial diversity with 6 strategies for improving inclusion in cancer studiesDigital Medicine Society rolls out initiative to improve diversity in clinical trialsFDA's Richard Pazdur, sector leaders push for private-public partnership to boost DEI in cancer drug development  See omnystudio.com/listener for privacy information.

In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15.  To learn more about the topics in this episode:  Fierce Medtech's Fierce 15 of 2023See omnystudio.com/listener for privacy information.

This week on “The Top Line,” we’re speaking with Jared Baeten, MD, Ph.D., Vice President, HIV Clinical Development, Gilead Sciences about how advancements in HIV treatment research have enabled individuals to lead longer and healthier lives by taking and staying on medication. Nevertheless, HIV persists as a significant public health challenge. To end the HIV epidemic, it is crucial to go beyond a biomedical approach and fully integrate social determinants of health into the collective response. Not everyone is achieving long-term success.  Long-term success involves meeting more than the United Nations’ goals of ending the epidemic by 2030. Treatment selection can help prioritize long-term outcomes from the very beginning. There are several other key factors for people with HIV and their healthcare providers to consider when assessing treatment choices, such as the resistance and safety profile of a treatment, drug-to-drug interaction potential, and comorbid conditions. This podcast is brought to you by Gilead Sciences. Visit gileadhivtogether.com to learn more about Gilead’s unique collaborations worldwide and the work to help end the HIV epidemic.See omnystudio.com/listener for privacy information.

The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This decision follows an investigation into the new safety signal from postmarketing adverse event reports and clinical trials.  In today’s episode, Fierce Pharma’s Angus Liu talks with regulatory experts Mwango Kashoki, M.D., SVP, Global Head of Regulatory Strategy at Parexel, and Steve Winitsky, M.D., VP, Technical, Regulatory Strategy at Parexel, to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line.   To learn more about the topics in this episode:  FDA wants classwide boxed warning on all commercial CAR-T therapies amid secondary cancer safety probeAmid high-profile CAR-T safety probe, FDA’s Peter Marks offers first glimpse at data under review  See omnystudio.com/listener for privacy information.

This week on “The Top Line,” we explore the impact of environmental, social and governance measures, commonly known as ESG, on the pharmaceutical industry.  Fraiser Kansteiner of Fierce Pharma engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights. Greffet makes a compelling business case for integrating ESG into the core of drugmakers' DNA. He also discusses Eli Lilly’s specific ESG initiatives, illustrating how these strategies connect to the company’s extensive history.  To learn more about the topics in this episode:  Patient groups want pharma to improve on ESG—and are pushing for a seat at the tableSetting sights on suppliers: How biopharma is tackling the environment in its ESG commitmentsSeeing green, AstraZeneca lays down £100M for 15-year renewable gas project in UKGilead receives awards, pledges commitment to COVID, the environment and inclusion in 2023  See omnystudio.com/listener for privacy information.

Gene editing’s therapeutic application has transitioned from hypothetical to reality, marked by the recent approval of a CRISPR-based therapy for sickle cell and beta thalassemia. In the wake of these developments, new biotech companies are springing up spurred by advancements that redefine what conditions might soon become treatable.   One contender in this rapidly changing landscape is Verve Therapeutics. This week on "The Top Line," Fierce Biotech’s Max Bayer sits down with the company’s CEO Sekar Kathiresan, M.D., to discuss how Verve intends to distinguish itself. They also chat about what drove Dr. Kathiresan to biotech after more than 20 years as a cardiologist and geneticist.   To learn more about the topics in this episode:  Verve Therapeutics unveils its lead program—a one-and-done treatment for genetic high cholesterolLilly beams up Verve gene therapy programs for $600M from deal-hungry BeamVerve shows base editing works in humans in first clinical data—and is punished by investorsVerve's base editing hold lifted, starting a thaw on a regulatory blockade that sent peers ex-US  See omnystudio.com/listener for privacy information.

This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. To learn more about the topics in this episode: Top 10 most anticipated drug launches of 2024BMS unwraps $14B deal for Karuna, adding a schizophrenia drug awaiting FDA OKBristol Myers Squibb has targeted launch plan for ‘multi-billion-dollar opportunity’ in Karuna schizophrenia drugMeet Madrigal Pharmaceuticals, which wants to be your liver's No. 1 fan  See omnystudio.com/listener for privacy information.

Should physicians consider the psychological status of patients more when developing and delivering treatment plans? What knowledge barriers are there to this? And how can these barriers be overcome? These questions lie at the heart of what John Kane has been pursuing as a healthcare communications and education expert for more than 30 years. As Managing Director of MedThink Communications, having run his own agency for 17 years, he works with the simple mission to "turn information into outcomes." In this episode of The Top Line podcast, John explores the link between a proper understanding of psychological factors and likely success of treatments. The conversation then moves on to discussing some of the key challenges faced by the medical industry in leveling the playing field between biological and psychological knowledge. Effective education and communication, he says, are a fundamental part of any solution. Want to hear more from John? Listen to the podcast today.See omnystudio.com/listener for privacy information.

In this episode, Dr. Beate Mueller-Tiemann, Chief Technology Officer at Cytiva, joins Fierce Life Sciences’s Stephanie Butler. Having spent almost all of her career working within large pharmaceutical enterprises such as Sanofi and Bayer, Beate made the switch to Cytiva in the early part 2023. Her role at Cytiva involves overseeing teams which create and bring high-quality products and innovative manufacturing and R&D processes closer to patients. Beate also keenly supports female talents through participation in mentoring programs. Additionally, she is a member of FiDAR, an association which seeks to increase the representation of women on German corporate boards. During the conversation, Beate discusses her passion for technology and how her career has been defined by working with technology to bring innovation and treatments to patients and improve health outcomes. She also touches on the ongoing work Cytiva is engaged in, as well as the importance of collaboration in driving R&D progress. Tune in to the podcast to learn more. Check out this year's Fierce 50 honorees: https://fierce50.fiercelifesciences.com/See omnystudio.com/listener for privacy information.

While generative AI has dominated the spotlight in the past year, machine learning programs have already been significantly impacting patients and physicians for several years. The question now arises: how will the emergence of programs like ChatGPT, coupled with increasing calls to scrutinize their safety, influence the adoption of new AI programs and diagnostics in healthcare?   This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath.  To learn more about the topics in this episode:  2024 forecast: Will generative AI find what it needs to deliver for patients? FDA to form advisory committee for digital health and AI US government to launch AI Safety Institute, develop standards for biotech R&D Biden to sign sweeping executive order pursuing 'safe, secure and trustworthy' AI development   See omnystudio.com/listener for privacy information.

While it’s a known fact that women, on average, live longer than men, a recent report unveils a nuanced reality—women also spend more of their lives grappling with poor health.  This week on “The Top Line,” Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, explores the root causes behind this disparity and the multifacted nature of the women’s health gap. She's joined by one of the lead authors of the report, Valentina Sartori, Ph.D., and a contributor to the report, Kelle Moley, M.D.   The report highlights that addressing the women’s health gap and investing in women’s health could inject $1 trillion into the economy annually by 2040, and Dr. Sartori explains why that number could be a significant underestimation.  While the report provides a clear understanding of the challenges, it also sheds light on viable pathways to close the women’s health gap and create a future where women not only live longer but lead healthier lives.  To learn more about the topics in this episode:   Closing the women’s health gap: A $1 trillion opportunity to improve lives and economiesWhite House launches new initiative aimed at investing in women's health researchOrganon finally offers a larger pharma model for women's health. But 'one company can't do it by itself'CMS unveils new model to support Medicaid agencies in offering whole-person maternal healthMenopause care is still a largely untapped market. Here's why investors and startups should dive in  See omnystudio.com/listener for privacy information.

At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. This week on “The Top Line,” Fierce Pharma’s Eric Sagonowsky and Kevin Dunleavy, both instrumental in creating the special report, are breaking down the numbers and sharing key insights into the landscape of drug approvals in 2023.  To learn more about the topics in this episode:  2023 drug approvals: After a down year, FDA signs off on a bounty of new meds, including 7 from Pfizer2022 drug approvals: After Aduhelm fiasco, FDA endorsements drop to 372021 drug approvals: In a year dominated by COVID, biopharma managed to deliver 55 new drugsSee omnystudio.com/listener for privacy information.

This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her.  To learn more about the topics in this episode:  Biotechs end year 'trading for nothing' as investors mull 'what is IPO-able today?'Fierce Biotech Layoff Tracker 2023Editor's Corner—When ASCO dueled with the world's biggest pop star, Swift Biotech was ready for itAlzheimer's meds are here. But for the Down syndrome community, it's still the 1980s  See omnystudio.com/listener for privacy information.

Paul Beresford and Lou Welebob of Agilent Technologies discuss how partnerships are vital in addressing the evolving needs of pharma for complex diagnostics and CDx development.   Discussions center around the importance of working with pharmaceutical companies to drive medical innovation and improve patient outcomes, helping to speed up the process of bringing the right treatments to the right patients at the right time.   Topics discussed include the importance of broadening technological focus on immunohistochemistry, such as bridging into digital biology and imaging as well as multiplexing. Spatial biology is touched upon, specifically looking at how spatial profiling can be used to determine cell proximity within the tumor microenvironment, potentially correlated to drug efficacy.   Looking ahead, both speakers point to the potential to use machine learning in key areas such as the development of assays for use across laboratories globally.   To discover the full range of insights from life sciences, diagnostics and applied chemical markets specialist Agilent Technologies, listen to the full podcast.See omnystudio.com/listener for privacy information.